New Jersey Drug Utilization Review Board
Virtual Platform
April 15, 2026

http://www.state.nj.us/humanservices/dmahs/boards/durb/

AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of meeting transcript for January 28, 2026, meeting
https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/1-2026/DURB_Transcript_January_2026.pdf

IV. Review of draft meeting summary for January 28, 2026, meeting (pages 4-8)

V. Secretary's report (page 9)

VI. Old Business
   A. Utilization Trends of GLP-1/GIP Agonists (pages 10-11)
   B. Utilization Trends of SGLT-2 Inhibitors (pages 12-13)
   C. Updated Protocol for Opzelura® (pages 14-16)
   D. Updated Protocol for Duchenne Muscular Dystrophy Products (pages 17-20)

VII. New Business
   A. Proposed Addendum to Protocol for Crysvita® (pages 21-23)
   B. Proposed Addendum to Protocol for Cystic Fibrosis Transmembrane Conductance Regulator Products (pages 24-26)
   C. Proposed Addendum to Protocol for Spinal Muscular Atrophy Products (pages 27-30)

VIII. A. Informational Highlights/Reports

1. Gainwell Technologies/NJ MCO 4th Quarter 2025 Prior Authorization Report
2. (page 31)
3. Summary of DURB Action Items (pages 32-36)
4. DHS/DOH Pharmacy Programs Top Drugs Report/Physicians Administered Drugs Report (by amount paid and by category):

FFS top drugs:
https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/4-2026/FFS_Top_Drugs_Report_by_Payment_%20January-2026.pdf

MCO top drugs:
https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/4-2026/MCO_Top_Drugs_Report_by_Payment_%20December-2025.pdf

FFS top drugs by category:
https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/4-2026/FFS_Top_Drugs_by_Category_by_Payment_%20January-2026.pdf

MCO top drugs by category:
https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/4-2026/MCO_Top_Drugs_by_Category_by_Payment_%20December-2025.pdf

FFS antiviral drugs:
https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/4-2026/FFS_Antiviral_Drugs_by_Payment_%20January-2026.pdf

B. Recent Guidelines

AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease
https://www.sciencedirect.com/science/article/pii/S0016508525060913?via%3Dihub

Transthyretin Cardiac Amyloidosis Evaluation and Management:2025 ACC Concise Clinical Guidance
https://www.jacc.org/doi/epdf/10.1016/j.jacc.2025.09.004

KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)
https://www.kidney-international.org/article/S0085-2538(25)00495-8/fulltext

Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association
https://www.lipidjournal.com/article/S1933-2874(26)00010-3/fulltext